AR074996A1 - Formas polimorficas de sal de clorhidrato de 3-(1-(3-(5-(1-metil-piperidin -4-ilmetoxi) -pirimidin-2-il)-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)- benzonitrilo y sus procesos de preparacion - Google Patents

Formas polimorficas de sal de clorhidrato de 3-(1-(3-(5-(1-metil-piperidin -4-ilmetoxi) -pirimidin-2-il)-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)- benzonitrilo y sus procesos de preparacion

Info

Publication number
AR074996A1
AR074996A1 ARP100100033A ARP100100033A AR074996A1 AR 074996 A1 AR074996 A1 AR 074996A1 AR P100100033 A ARP100100033 A AR P100100033A AR P100100033 A ARP100100033 A AR P100100033A AR 074996 A1 AR074996 A1 AR 074996A1
Authority
AR
Argentina
Prior art keywords
benzonitrile
piperidin
oxo
methyl
ilmetoxi
Prior art date
Application number
ARP100100033A
Other languages
English (en)
Inventor
Oliver Schadt
Christoph Saal
Dieter Dorsch
Frank Stieber
Clemens Kuehn
Heinz-Hermann Bokel
Axel Becker
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074996(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR074996A1 publication Critical patent/AR074996A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente se refiere a solvatos de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo de formula (1) y sus modificaciones cristalinas La presente también se refiere a procesos de preparacion de estas modificaciones cristalinas así como a su uso en el tratamiento y/o la profilaxis de condiciones fisiologicas y/o patofisiologicas, las cuales son causadas, mediadas y/o propagadas por la inhibicion, regulacion y/o modulacion de senales de transduccion de quinasas, en particular por la inhibicion de tirosina quinasas, por ejemplo condiciones patofisiologicas tales como cáncer.
ARP100100033A 2009-01-08 2010-01-08 Formas polimorficas de sal de clorhidrato de 3-(1-(3-(5-(1-metil-piperidin -4-ilmetoxi) -pirimidin-2-il)-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)- benzonitrilo y sus procesos de preparacion AR074996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09000140 2009-01-08

Publications (1)

Publication Number Publication Date
AR074996A1 true AR074996A1 (es) 2011-03-02

Family

ID=41572530

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100033A AR074996A1 (es) 2009-01-08 2010-01-08 Formas polimorficas de sal de clorhidrato de 3-(1-(3-(5-(1-metil-piperidin -4-ilmetoxi) -pirimidin-2-il)-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)- benzonitrilo y sus procesos de preparacion

Country Status (32)

Country Link
US (3) US8710058B2 (es)
EP (1) EP2373640B1 (es)
JP (2) JP5719781B2 (es)
KR (2) KR101730791B1 (es)
CN (1) CN102272121B (es)
AR (1) AR074996A1 (es)
AU (1) AU2009336839B2 (es)
BR (1) BRPI0922642B8 (es)
CA (4) CA3097370A1 (es)
CL (1) CL2011001356A1 (es)
CO (1) CO6400191A2 (es)
CY (1) CY1115631T1 (es)
DK (1) DK2373640T3 (es)
EA (1) EA019342B1 (es)
EC (1) ECSP11011248A (es)
ES (1) ES2522629T3 (es)
HK (1) HK1164856A1 (es)
HR (1) HRP20140908T1 (es)
IL (1) IL213829A0 (es)
MX (3) MX363848B (es)
MY (1) MY160017A (es)
NZ (1) NZ594404A (es)
PE (2) PE20120474A1 (es)
PL (1) PL2373640T3 (es)
PT (1) PT2373640E (es)
SG (2) SG10201504735QA (es)
SI (1) SI2373640T1 (es)
SM (1) SMT201400161B (es)
TW (1) TWI475997B (es)
UA (1) UA106220C2 (es)
WO (1) WO2010078897A1 (es)
ZA (1) ZA201105782B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201504735QA (en) * 2009-01-08 2015-07-30 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
WO2013139423A1 (en) * 2012-03-19 2013-09-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
CA2890273C (en) * 2012-11-02 2021-10-26 Merck Patent Gmbh A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
RU2016132401A (ru) * 2014-01-07 2018-02-13 Мерк Патент Гмбх Производное 6-оксо-1, 6-дигидро-пиридазина для применения для лечения почечно-клеточного рака (rcc)
BR112017012136A2 (pt) 2014-12-12 2018-01-02 Merck Patent Gmbh Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr
CA2981627C (en) 2015-04-03 2024-02-20 Suixiong Cai Solid pharmaceutical formulation of parp inhibitors and the use thereof
WO2016192831A1 (en) 2015-05-29 2016-12-08 Merck Patent Gmbh Compositions of anions and cations with pharmacological activity
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EP3786155B1 (en) * 2018-04-26 2023-08-16 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
CA3146384A1 (en) * 2019-07-10 2021-01-14 Merck Patent Gmbh Pharmaceutical preparation
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2022250350A1 (ko) 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
KR102489160B1 (ko) 2021-05-26 2023-01-18 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
EP4346829A1 (en) 2021-06-04 2024-04-10 Merck Patent GmbH Compounds for the treatment of glioblastoma
CN114394957B (zh) * 2021-12-24 2023-05-09 武汉九州钰民医药科技有限公司 Met抑制剂盐酸特泊替尼的制备方法
KR20230155324A (ko) 2022-05-03 2023-11-10 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169932B2 (en) * 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
WO2005016345A1 (en) * 2003-08-19 2005-02-24 Boehringer Ingelheim International Gmbh Multivitamin syrup for children or young adults
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
JP2008517896A (ja) * 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
EP1809621A1 (en) * 2004-11-02 2007-07-25 Pfizer, Inc. Methods of preparing indazole compounds
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
SG10201504735QA (en) * 2009-01-08 2015-07-30 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
ES2522629T3 (es) 2014-11-17
KR101730791B1 (ko) 2017-04-27
CA2949515C (en) 2018-10-23
KR20110111472A (ko) 2011-10-11
PT2373640E (pt) 2014-09-30
UA106220C2 (ru) 2014-08-11
ECSP11011248A (es) 2011-10-31
EA201101039A1 (ru) 2012-02-28
CA3014648A1 (en) 2010-07-15
MX363852B (es) 2019-04-05
CA2949515A1 (en) 2010-07-15
MY160017A (en) 2017-02-15
WO2010078897A1 (en) 2010-07-15
BRPI0922642B8 (pt) 2021-05-25
IL213829A0 (en) 2011-07-31
ZA201105782B (en) 2012-04-25
US9308205B2 (en) 2016-04-12
EP2373640A1 (en) 2011-10-12
TWI475997B (zh) 2015-03-11
JP2015038148A (ja) 2015-02-26
US20140200221A1 (en) 2014-07-17
CN102272121B (zh) 2014-12-10
CO6400191A2 (es) 2012-03-15
AU2009336839A1 (en) 2011-08-25
DK2373640T3 (da) 2014-10-06
AU2009336839B2 (en) 2015-12-24
SI2373640T1 (sl) 2014-11-28
SG10201504735QA (en) 2015-07-30
KR20170047408A (ko) 2017-05-04
CN102272121A (zh) 2011-12-07
BRPI0922642B1 (pt) 2020-09-29
PL2373640T3 (pl) 2014-12-31
CA3014648C (en) 2021-06-01
MX350894B (es) 2017-09-22
US20110269767A1 (en) 2011-11-03
MX363848B (es) 2019-04-05
EP2373640B1 (en) 2014-07-30
PE20141317A1 (es) 2014-09-26
US9289427B2 (en) 2016-03-22
CL2011001356A1 (es) 2011-09-30
CA2749012C (en) 2017-01-31
JP5860126B2 (ja) 2016-02-16
SMT201400161B (it) 2015-01-15
HRP20140908T1 (hr) 2014-11-07
US20150148351A1 (en) 2015-05-28
JP5719781B2 (ja) 2015-05-20
NZ594404A (en) 2013-04-26
SG172831A1 (en) 2011-08-29
CA3097370A1 (en) 2010-07-15
CA2749012A1 (en) 2010-07-15
JP2012514609A (ja) 2012-06-28
CY1115631T1 (el) 2017-01-04
KR101829595B1 (ko) 2018-02-14
US8710058B2 (en) 2014-04-29
MX2011007322A (es) 2011-07-29
EA019342B1 (ru) 2014-02-28
HK1164856A1 (en) 2012-09-28
TW201029655A (en) 2010-08-16
BRPI0922642A2 (pt) 2016-01-05
PE20120474A1 (es) 2012-05-04
AU2009336839A8 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
AR074996A1 (es) Formas polimorficas de sal de clorhidrato de 3-(1-(3-(5-(1-metil-piperidin -4-ilmetoxi) -pirimidin-2-il)-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)- benzonitrilo y sus procesos de preparacion
CR11207A (es) Compuestos organicos
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
CO6170360A2 (es) Derivados de pirimidinil - piridazinona
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
BR112012033241A2 (pt) [1,8]naftiridinas substituídas por 2,4-diarila como inibidores de quinase para uso contra câncer
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
NI201100122A (es) Derivados de isoxazol para uso como reguladores del crecimiento de plantas.
BR112015007937A2 (pt) formas cristalinas de um inibidor de fator xia
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
CY1122468T1 (el) Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου
TN2011000428A1 (en) Uses of nk receptor antagonists
NZ630803A (en) Optically active pde10 inhibitor
ECSP099673A (es) Formas sólidas de un inhibidor de cinasa raf
MX2010005488A (es) Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina.
ECSP11011219A (es) Nuevas formas polimórficas de dihidrógeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación.
NZ608708A (en) Novel gpr 119 agonists
TN2009000147A1 (en) Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione
CL2009001088A1 (es) Forma cristalina (ii) de (1r,4r)-4-(1,1-dimetiletilsulfonamido)-n-(5-(trifluorometil) piridin-2-il) ciclohexancarboxamida; procesos de preparacion; utiles como antagonistas del receptor npyy5.
TH108525A (th) รูปพหุสัณฐานชนิดใหม่ของเกลือไฮโดรคลอไรด์ของ 3-(1-{3-[5-(1-เมธิล-พิเพอริดิน-4-อิลเมธอกซิ)-พิริมิดิน-2-อิล]-เบนซิล}-6-ออกโซ-1,6-ไดไฮโดร-พิริดาซิน-3-อิล)-เบนโซไนไทรล์ และกรรมวิธีการผลิตพวกมัน
TH135036A (th) รูปแบบโพลีมอร์ฟิคใหม่ของ 6-(1-เมทธิล-1h-ไพราโซล-4-อิล)-2-{3-[5-(2-มอร์โฟลีน-4-อิล-เอทธอกซี)-ไพริมิดีน-2-อิล]-เบนซิล}-2h-ไพริดาซีน-3-โอน ไดไฮโดรเจนฟอสเฟต และกระบวนการผลิตผลึกดังกล่าว
CU23680B7 (es) Derivados de oxazol sustituidos y su uso como inhibidores de tirosina quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal
FB Suspension of granting procedure